A wireless, non-invasive patch that provides continuous monitoring of pulmonary fluid levels to prevent heart failure readmissions has been prescribed to its first commercial patient, Chelmsford, Mass.-based medical device company Zoll announced June 10.
Douglas Horstmanshof, MD, of the Integris Baptist Medical Center in Oklahoma City, was the first to prescribe Zoll's µCor Heart Failure and Arrhythmia Management System (HFAMS). Using radiofrequency technology, the sensor records and stores patient data such as Thoracic Fluid Index, heart rate, respiration rate, activity, posture and heart rhythm, then transmits the data to Zoll's diagnostic testing facility and the prescribing physician.
HFAMS was designed to reduce hospitalizations for heart failure patients; an estimated 50 percent of individuals hospitalized for heart failure are readmitted within six months, and most within 30 days of discharge. The system uses proprietary algorithms to monitor patient data and alert physicians to signs of deterioration in a patient's condition well before hospitalization would be required.
More articles about health IT:
AI-powered low-dose CT imaging is faster, safer, more accurate than other methods
5 hospitals, health systems already implementing AI
IBM Watson Health, Medtronic app predicts hypoglycemic events with up to 90% accuracy